Nous cherchons a recruter un/une Chargé-e de gestion administrative et d'aide au pilotage opérationnel - J2C46 (BAP J, IGE)

Mission 1 : responsable administratif et financier

• Assurer la coordination financière de l’unité : gestion des dotations financières récurrentes, des contrats de recherche publics et industriels avec la mise en place, la participation à la rédaction des conventions, et le suivi des dépenses
• Assurer la gestion des commandes : logiciel SIFAC et SAFIR, réception, services faits
• Elaborer les tableaux de bord et les bilans financiers - Gérer les gratifications de stage
• Gérer les missions (ordres de mission : logiciel SIFAC et SAFIR -déplacements & hébergements : logiciel SIFAC mission, & inscriptions congrès)
• Préparer et rédiger les réponses aux enquêtes des tutelles
• Participer à la gestion de la Communication interne de l’Unité

Mission 2 : gestion des ressources humaines

•  Rédiger et gérer les contrats de travail CDD
• Rédiger et gérer les conventions de stage
• Accueillir les nouveaux entrants
• Préparer et rédiger les réponses aux enquêtes des tutelles

Mission 3 : gestion et suivi des projets de recherche

• Assurer la gestion et le suivi financier des projets nationaux et internationaux
• Gérer les ressources humaines liées à des projets de recherche nationaux et internationaux
• Assurer la veille scientifique et des appels d’offres en lien avec la thématique des projets de recherche nationaux et internationaux
• Participer à la rédaction et au montage des dossiers de demandes de financements
• Participer à l’organisation et à l’animation des réseaux scientifiques des projets de recherche nationaux et internationaux

Savoir / connaissances 

• Maîtrise des règles administratives et des procédures de gestion de l'Université Rouen Normandie et idéalement de l’INSERM - Maîtrise des applications budgétaires de l'Université Rouen Normandie (Application SIFAC) et idéalement de l’INSERM (Application SAFIR), pour les dépenses et les missions.
• Connaissances scientifiques et biologiques de base

Savoir faire / compétences opérationnelles

• Comptabilité, utilisation des logiciels de gestions de commande, de gestion de mission, etc.
• Connaissance des règles de la finance publique
• Rédaction et mise à jour régulière de tableaux de suivi financier et de ressources humaines
• Veille des ressources et dépenses - Rédaction et rendu de rapports ou synthèses
• Veille au respect de la conformité réglementaire et des règles financières et de la valorisation
• Organisation du Conseil de laboratoire et rédaction du procès-verbal
• Animation et gestion de réseaux Savoir être / compétences comportementales
• Disponibilité, adaptabilité et réactivité face aux changements des règles administratives et financières
• Rigueur et fiabilité dans la gestion des dossiers complexes, respect des règles de confidentialité

Voir procedure sur: La communauté universitaire - Liste des postes BIATSS publiés au mouvement interne au fil de l'eau (univ-rouen.fr)

Pr Helene Eltchaninoff has been elected vice-president of the SFC - Société Francaise de Cardiologie

La doctorante Manon Monmirel, dirigée par Dr Antoine Ouvrard-Pascaud dans notre unité,  est laurate du Prix étudiantes engagées dans un cursus scientifique de la part des L’université de Rouen Normandie, l’INSA Rouen Normandie et Janssen France avec l’association Femmes et Sciences

Myocardial infarction (MI) triggers a wound healing response that involves rapid recruitment of immune cells, notably myeloid cells, to the heart. This innate immune response is required for efficient healing, and alteration of its kinetics may contribute to poor infarct remodeling driving heart failure development. In the latest issue of Nature Communications, the team led by Dr. Fraineau described for the first time the role of an epigenetic switch in regulating the kinetics and profiles of the innate immune response post-MI. Specifically, they uncovered that an epigenetic transcriptional repressive enzyme, named EZH2, serves as an epigenetic check-point during polarization of monocytes toward an immunomodulatory pro-regenerative macrophage phenotype. Using an epigenetic pharmacological inhibitor of EZH2, this check-point can be suppressed, thus enhancing the transcriptomic program resulting in generation of more immunomodulatory macrophages. This led to an acceleration of the innate immune response after MI, resulting in reduced deleterious infarct scar remodeling, and prevention of post-MI aggravation of cardiac dysfunction. Altogether, Fraineau et al. identified an original epigenetic mechanism governing macrophage polarization toward either proinflammatory or immunomodulatory phenotypes, thus revealing epigenetic mechanisms as a novel therapeutic target to improve inflammatory kinetics post-MI to prevent heart failure development.

See further: open access article or video presentation by Dr Fraineau 

The MSCA Winning-Normandy project PROTECT: "Pharmacological tReatment Of acuTe dECompensaTed heart failure: focus on metabolic remodeling" was initiated in 2022 in our laboratory. This project, led by Postdoctoral researcher Francesca Lockwood together with Pr Paul Mulder, will investigate the molecular, and notably metabolic, changes that occur during Acute Decompensated Heart Failure (ADHF).  This project is developed in parallel to a recent ANR project (2019-2022) focused on ADHF: RESIST-HF.

Biography:

Francesca Lockwood has multidisciplinary experience in areas including cancer and cardiovascular pathophysiology and pharmacology from both academia and the biotech sector.

Francesca Lockwood undertook a Pharmacology degree with honours (awarded in 2016) from the University of Portsmouth (United Kingdom) and during this programme she obtained an Erasmus placement where she worked at Inserm U1096 (Rouen) , in 2015, investigating ‘Cardiovascular effects of the IL-1β Antibody Gevokizumab’, which she used for her bachelor thesis.

Alongside completing the final year of her bachelors, Francesca researched at the Institute of Biomedical & Biomolecular Science at the University of Portsmouth on ‘The effects of stress on the locus coeruleus and its contribution to Parkinson’s disease’. The data generated contributed to a successful funding application ‘The Role of the Brain Locus Coeruleus Nucleus in Parkinson’s Disease-induced stress and anxiety’ to the project supervisor Dr Jermone Swinny of £224,978 from Parkinson’s UK, awarded in 2016. Francesca then explored ‘Chemoresistance in glioblastoma multiforme through REDOX adaptations’ during her Masters of Research degree at the Brain Tumour institute at the University of Portsmouth which entailed full time research while completing the degree (awarded in 2017).

Francesca then moved into the biotech industry at Primer Design, Southampton, UK which involved technical sales/advice, team management and business strategy guidance. During this position Francesca obtained a Research assistant and Doctoral Research fellow position at Ulleval Hospital - University of Oslo, Norway, to investigate ‘Mechanisms of cardiac fibrosis from cardiac hemodynamic overload’. While in this position, Francesca was headhunted by a global private biotech company, developing cancer vaccines in an industrial scientist position, and was quickly promoted to project leader. After around 5 months at this company Francesca was offered the position of CEO of the US daughter company.

During this time Francesca’s application for the Winning Normandy grant with Inserm U1096 was successful and she chose this position instead of CEO and started in October 2022. In this position Francesca will be investigating the ‘Metabolic mechanisms during cardiac remodelling in order to explore therapeutics targets and to investigate the efficacy of potential therapeutics on these pathways’.